These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10945717)

  • 1. At what level of coronary heart disease risk should a statin be prescribed?
    Gaw A; Packard CJ
    Curr Opin Lipidol; 2000 Aug; 11(4):363-7. PubMed ID: 10945717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Debate: at what level of coronary heart disease risk should a statin be prescribed?
    Jackson PR; Ramsay LE
    Curr Opin Lipidol; 2000 Aug; 11(4):357-61. PubMed ID: 10945716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
    Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study.
    Shepherd J
    Am J Cardiol; 2001 Mar; 87(5A):19B-22B. PubMed ID: 11256845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
    Pickin DM; McCabe CJ; Ramsay LE; Payne N; Haq IU; Yeo WW; Jackson PR
    Heart; 1999 Sep; 82(3):325-32. PubMed ID: 10455083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
    Jacobson TA
    Curr Opin Lipidol; 1997 Dec; 8(6):369-74. PubMed ID: 9412778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of statins.
    Reckless JP
    Curr Opin Lipidol; 2000 Aug; 11(4):351-6. PubMed ID: 10945715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoeconomics.
    Rockson SG
    Curr Atheroscler Rep; 2000 Mar; 2(2):144-50. PubMed ID: 11122738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selections from current literature: the fight over fat: is pharmacological lipid lowering useful for coronary primary prevention?
    Green L
    Fam Pract; 1997 Oct; 14(5):411-5. PubMed ID: 9472378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins: where are we now?
    Cowie MR
    Hosp Med; 2000 Nov; 61(11):789-92. PubMed ID: 11198749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of coronary heart disease prevention strategies in adults.
    Brown AD; Garber AM
    Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering therapy for the primary prevention of coronary heart disease.
    Gotto AM
    J Am Coll Cardiol; 1999 Jun; 33(7):2078-82. PubMed ID: 10362217
    [No Abstract]   [Full Text] [Related]  

  • 13. Simvastatin: building on success.
    Gaw A
    Hosp Med; 2001 Jan; 62(1):29-32. PubMed ID: 11211458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of recent trials with b-hydroxy-b-methylglutaryl coenzyme A reductase inhibitors for hypertension management.
    Haq IU; Wallis EJ; Jackson PR; Yeo WW; Ramsay LE
    J Hypertens; 1999 Nov; 17(11):1641-6. PubMed ID: 10608479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid lowering in patients with diabetes mellitus: what coronary heart disease risk threshold should be used?
    Rowland Yeo K; Yeo WW
    Heart; 2002 May; 87(5):423-7. PubMed ID: 11997409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.
    Eidelman RS; Lamas GA; Hennekens CH
    Arch Intern Med; 2002 Oct; 162(18):2033-6. PubMed ID: 12374510
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipid-lowering drug therapy in elderly patients.
    Berthold HK; Gouni-Berthold I
    Curr Pharm Des; 2011; 17(9):877-93. PubMed ID: 21418034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe.
    Hermansson J; Kahan T
    Pharmacoeconomics; 2018 Feb; 36(2):205-213. PubMed ID: 29079929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
    Heller DJ; Coxson PG; Penko J; Pletcher MJ; Goldman L; Odden MC; Kazi DS; Bibbins-Domingo K
    Circulation; 2017 Sep; 136(12):1087-1098. PubMed ID: 28687710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.